Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 71Lung Neoplasms 32Triple Negative Breast Neoplasms 23Breast Neoplasms 19Small Cell Lung Carcinoma 15Ovarian Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Endometrial Neoplasms 13Neoplasms 12Parkinson Disease 4, Autosomal Dominant Lewy Body 10Fallopian Tube Neoplasms 10Neoplasm Metastasis 9Colorectal Neoplasms 6Urinary Bladder Neoplasms 5Carcinoma 5Adenocarcinoma of Lung 5Esophageal Neoplasms 4Uterine Cervical Neoplasms 3Pathologic Complete Response 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Mesothelioma 3Melanoma 3Lung Diseases 3Head and Neck Neoplasms 3Esophageal Squamous Cell Carcinoma 3Central Nervous System Neoplasms 3Uterine Neoplasms 2Thoracic Neoplasms 2Sarcoma 2

Interventions

temsirolimus 1ixabepilone 1Taxes 1Sirolimus 1Paclitaxel 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Adenocarcinoma × Carboplatin × 30 days × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡